Alternative Treatment Strategies for Stenotrophomonas Maltophilia Pneumonia
Study Details
Study Description
Brief Summary
Multi center, retrospective chart review of patients admitted to MHS hospitals from April 1, 2017 to March 31, 2022. Patients will be identified through the electronic medical record, and data from those that meet the study inclusion and exclusion criteria will be analyzed. Minimum inhibitory concentration (MIC) data will be interpreted per Clinical & Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance. Multivariable logistic regression will be performed to determine predictors of mortality for S. maltophilia isolates.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Detailed Description
Stenotrophomonas maltophilia is an aerobic, non-fermenting, Gram-negative bacillus recognized by the World Health Organization as one of the leading multi-drug resistant nosocomial pathogens worldwide. The Investigators aim to examine differences in clinical outcomes and failure rates between standard and alternative treatment strategies such as minocycline (or moxifloxacin, ciprofloxacin, ceftazidime) alone or in combination with TMP-SMX, alternative TMP-SMX dosing regimens, or variations in durations of therapy for the treatment of S. maltophilia infections within Methodist Health System (MHS).
Study Design
Outcome Measures
Primary Outcome Measures
- the difference in clinical failure rates between standard and alternative therapy [30 days]
defined as meeting any of the following criteria: 1) isolation of S. maltophilia from a subsequently collected culture from the same site of index culture after at least 48 hours of therapy; 2) alteration of monotherapy after at least 48 hours of treatment for either an adverse event or concern for clinical failure; or 3) 30-day in-hospital all-cause mortality.
Secondary Outcome Measures
- Clinical outcomes such as ICU LOS [30 days]
related/attributable mortality, and rates of serious adverse events.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
≥18 years of age
-
- maltophilia isolated on respiratory or blood culture
Exclusion Criteria:
- Those that do not meet the inclusion criteria outlined in Section 4.1.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Methodist Dallas Medical Center | Dallas | Texas | United States | 75201 |
Sponsors and Collaborators
- Methodist Health System
Investigators
- Principal Investigator: Mathew Crotty, PharmD, Methodist Dallas Medical Center
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 034.PHA.2022.A